Form 4: Arrowhead CEO Sells Shares for Tax Obligations

Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 13,187 shares of common stock on January 2, 2026, to cover tax withholding obligations under a pre-arranged 10b5-1 plan.

Summary

• Christopher Anzalone, Chief Executive Officer and Director of Arrowhead Pharmaceuticals, Inc. (ARWR), sold a total of 13,187 shares of common stock.
• The sales occurred on January 2, 2026, and were executed pursuant to a Rule 10b5-1 trading plan.
• The first transaction involved the disposition of 7,416 shares at a weighted average price of $65.88 per share, with individual transaction prices ranging from $65.28 to $66.20.
• The second transaction involved the disposition of 5,771 shares at a weighted average price of $66.39 per share, with individual transaction prices ranging from $66.21 to $66.58.
• The primary purpose of these dispositions was to satisfy tax withholding obligations related to equity compensation.
• Following these transactions, Anzalone's direct beneficial ownership stands at 3,792,739 shares of common stock, which includes shares underlying Restricted Stock Units, some of which are still subject to vesting conditions.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's for a routine and expected reason (tax withholding) and executed under a 10b5-1 plan, which suggests transparency and pre-planning rather than a negative signal about the company's prospects.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and transparent transaction rather than an opportunistic or reactive sale.
• The primary reason for the disposition was to satisfy tax withholding obligations, which is a common and routine event for executives receiving equity compensation and does not typically signal a negative outlook on the company.

Negatives

• A reduction in the CEO's direct beneficial ownership, even for tax purposes, represents a decrease in his direct stake in the company.

Risks

• No specific new risks are introduced by this routine Form 4 filing. The general perception of insider selling, even for tax purposes, could be misinterpreted by some investors if the context of tax withholding and 10b5-1 plans is not fully understood.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• Partial disposition of shares to satisfy tax withholding obligations.

Industry Context

This routine insider transaction by the CEO of Arrowhead Pharmaceuticals is typical for executives receiving equity compensation and does not indicate any specific industry trends or competitive shifts. It is a standard disclosure of a planned stock sale for tax purposes, common across various industries for publicly traded companies.

Related Party Transactions

• The sale of shares by Christopher Anzalone, the CEO and a Director, constitutes a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale for tax purposes and is unlikely to have a significant direct impact on shareholders, beyond the disclosure of a slight reduction in the CEO's direct ownership. The 10b5-1 plan mitigates concerns about opportunistic selling.
• Employees: No direct impact on employees is mentioned or implied by this filing.
• Customers/Suppliers/Creditors: No direct impact on customers, suppliers, or creditors is mentioned or implied by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine insider sale by the CEO to cover tax withholding obligations, executed under a pre-arranged 10b5-1 plan. Such transactions are common for executives receiving equity compensation and do not typically signal a change in the company's fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing. A 'hold' recommendation is maintained, pending further fundamental analysis.

Keywords

Arrowhead Pharmaceuticals, ARWR, Christopher Anzalone, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Tax Withholding, Equity Compensation